Abstract: The invention provides a method for the immunological determination of an antibody against a drug antibody in a sample using a double antigen bridging immunoassay comprising a capture drug antibody and a tracer drug antibody, characterized in that the capture drug antibody is a mixture of said drug antibody conjugated to the solid phase at at least two different antibody sites and the tracer drug antibody is a mixture of said drug antibody conjugated to the detectable label at at least two different antibody sites.

Abstract: The present invention relates to in vitro methods for determining the presence or absence of an anti-drug antibody (ADA) or drug/ADA immunecomplexes in a minipig sample. The invention further relates to antibodies specifically binding to minipig IgG that are applicable in the methods of the invention.

Abstract: The present invention relates to in vitro methods for determining the presence or absence of an anti-drug antibody (ADA) or drug/ADA immunecomplexes in a minipig sample. The invention further relates to antibodies specifically binding to minipig IgG that are applicable in the methods of the invention.

Abstract: Herein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 ?g/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody.

Abstract: The invention provides a method for the immunological determination of an antibody against a drug antibody in a sample using a double antigen bridging immunoassay comprising a capture drug antibody and a tracer drug antibody, characterized in that the capture drug antibody is a mixture of said drug antibody conjugated to the solid phase at at least two different antibody sites and the tracer drug antibody is a mixture of said drug antibody conjugated to the detectable label at at least two different antibody sites.

Abstract: Herein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 ?g/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody.

Abstract: Herein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 ?g/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody.

Abstract: Herein are reported the cell lines DSM ACC3006, DSM ACC3007, and DSM ACC3008, as well as the antibodies obtained from the cell lines and the use of an antibody obtained from the cell lines in an immunoassay. Also are reported antibodies binding to human or chimpanzee IgG and not binding to canine and marmoset IgG and antibodies specifically binding to an IgG 1 that comprises a kappa light chain constant domain.

Abstract: The invention provides an antibody binding specifically to Cynomolgus IgG characterized by not binding to Human IgG, and a method for the immunological determination of an immune complex (DA/ADA complex) of a drug antibody (DA) and an antibody against said drug antibody (anti-drug antibody, ADA) in a sample of a monkey species using a double antigen bridging immunoassay.

Abstract: Herein are reported a monoclonal antibody specifically binding to a human IgG1 antibody and not specifically binding to the immunoglobulin of an experimental animal and the use of the antibody in immunoassays.

Abstract: The present invention is directed to an anti-idiotype antibody binding to the complementary determining region of an antibody against the amyloid ? peptide. In one embodiment said antibody binds to the same epitope or an overlapping epitope as the antibody obtainable from the cell line DSM ACC2939. Also reported is an immunoassay for the determination of an antibody against the amyloid ? peptide and for determination of an anti-idiotype antibody binding to an antibody against the amyloid ? peptide.

Abstract: Herein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 ?g/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody.

Abstract: Herein are reported a monoclonal antibody specifically binding to a human IgG1 antibody and not specifically binding to the immunoglobulin of an experimental animal and the use of the antibody in immunoassays.

Abstract: The invention provides a method for the immunological determination of an antibody against a drug antibody in a sample using a double antigen bridging immunoassay comprising a capture drug antibody and a tracer drug antibody, characterized in that the capture drug antibody is a mixture of said drug antibody conjugated to the solid phase at at least two different antibody sites and the tracer drug antibody is a mixture of said drug antibody conjugated to the detectable label at at least two different antibody sites.

Abstract: The invention provides an antibody binding specifically to Cynomolgus IgG characterized by not binding to Human IgG, and a method for the immunological determination of an immune complex (DA/ADA complex) of a drug antibody (DA) and an antibody against said drug antibody (anti-drug antibody, ADA) in a sample of a monkey species using a double antigen bridging immunoassay.

Abstract: A composition comprising a conjugate of an anti-idiotype antibody specifically binding to a CDR region of a parent antibody and method of using polyclonal human serum immunoglobulin of class E, G, M, or A, and the use of said composition as a standard in an immunoassay is presented.

Abstract: The present invention is directed to an anti-idiotype antibody binding to the complementary determining region of an antibody against the amyloid ? peptide. In one embodiment said antibody binds to the same epitope or an overlapping epitope as the antibody obtainable from the cell line DSM ACC2939. Also reported is an immunoassay for the determination of an antibody against the amyloid ? peptide and for determination of an anti-idiotype antibody binding to an antibody against the amyloid ? peptide.

Abstract: The present invention is directed to an anti-idiotype antibody binding to the complementary determining region of an antibody against the amyloid ? peptide. In one embodiment said antibody binds to the same epitope or an overlapping epitope as the antibody obtainable from the cell line DSM ACC2939. Also reported is an immunoassay for the determination of an antibody against the amyloid ? peptide and for determination of an anti-idiotype antibody binding to an antibody against the amyloid ? peptide.

Abstract: Herein are reported the cell lines DSM ACC3006, DSM ACC3007, and DSM ACC3008, as well as the antibodies obtained from the cell lines and the use of an antibody obtained from the cell lines in an immunoassay. Also are reported antibodies binding to human or chimpanzee IgG and not binding to canine and marmoset IgG and antibodies specifically binding to an IgG1 that comprises a kappa light chain constant domain.

Abstract: The invention relates to a process for the production of a biomolecule-linker conjugate of uniform stochiometry. It especially relates to a conjugate consisting of a biomolecule of a molecular weight between 5 kD and 500 kD and a hydrophilic linker molecule said linker having a molecular weight between 1 and 15 kD and between 4 and 60 charged residues, characterized in that said conjugate comprises at least one biomolecule-linker product of uniform stoichiometry in a pre-selected amount.